AstraZeneca’s Forxiga Gets EU Nod for Chronic Kidney Disease

AstraZeneca’s Forxiga (dapagliflozin) has received EU approval for treatment of chronic kidney disease in adults with and without type-2 diabetes.

The approval was supported by results from a phase 3study in which Forxiga combined with standard care reduced the relative risk of worsening of renal function, onset of end-stage kidney disease, or risk of cardiovascular or renal death by 39 percent vs. placebo.

The European Commission previously approved Forxiga in November 2020 for treatment of adult patients with symptomatic chronic heart failure. The drug is marketed as Farxiga in the U.S.